

---

## The Pezcoller Foundation Symposia

### XI Pezcoller Symposium

#### **Molecular Horizons in Cancer Therapeutics**

June 5, 6 & 7, 1999; Rovereto, Italy

---

*Co-chairs:*

E.Mihich and D.Livingston

*Program Committee:*

Drs. E.Mihich, D.Livingston, G.Draetta,  
A. Lanzavecchia, A.Matter, F.McCormick

---

The XI Pezcoller Symposium will be held in Rovereto, Italy, from 5 - 7 June, 1999. It will be entitled "Molecular Horizons in Cancer Therapeutics" and will be focused on cutting edge approaches to the development of new ideas and methodologies in cancer therapeutics. It will include a discussion of new strategies in developing chemical knowledge and compounds of potential interest in cancer therapeutics. A session will be devoted to modern technologies used in drug discovery, new screening strategies and the identification of gene determinants of drug action. A session will be devoted to discussion of immunological and biological approaches to cancer therapeutics with particular emphasis on mechanisms of antigen presentation and of non-invasive imaging technology for the study of antiangiogenesis compounds. A session will be devoted to discussions of immunological and biological approaches to cancer therapeutics with particular emphasis on mechanisms of antigen presentation and on non-invasive imaging technology for the study of anti-angiogenesis compounds. A session will be devoted to interference with signaling including the effects of small chemical inhibitors. A final session will be devoted to interference with cell regulatory function including the role of p300/CDP, E2F, F-box protein p45SKP2, the regulation of p53 and clinical studies of signal transduction inhibition.

The multidisciplinary discussions to be held at this Symposium are expected to clarify issues pertinent to the topics mentioned above. Because equal time is allocated to presentation and to discussion, opportunities are provided for intensive interactions and cross stimulation among participants. In addition to the presentation by invited speakers, there will be also a session of posters with submissions relevant to the topics discussed.

---

## Program

### June 5

8:30 Registration

9:00 Pezcoller Foundation Officers Welcome & Introductory Remarks

9:15 Enrico Mihich Focus & Goals

### AM, Session I, New Chemical Strategies

Co-Chairmen: Joel Huberman and Michael Eck

9:30 Roland Burli Regulation of transcription by synthetic DNA binding ligands

10:00 Discussion

10:30 Coffee Break

11:00 Alfred Wittinghofer The GTPase reaction of Ras: A new target for anti-cancer therapy

11:30 Discussion

12:00 Ernest Laue Structure of the INK4/Cdk6 complex: Control of the G1 phase of the cell-cycle

12:30 Discussion

13:00 Lunch

### PM, Session II, Drug Discovery Technologies

Co-Chairmen: Brian Leyland-Jones and Andrew Simpson

14:00 Scott Lowe Control of apoptosis and senescence by cancer genes

14:30 Discussion

15:00 Andrew Pakula New approaches for anticancer drug discovery: Affinity-based high throughput screening technology provides access to novel targets

15:30 Discussion

16:00 Rakesh Jain Non-invasive monitoring of gene expression and function in vivo

16:30 Discussion

17:00 Adjourn

### June 6

### AM, Session III, Biologicals

Co-Chairmen: Elizabeth Repasky and Jonathan Howard

8:30 James Allison Manipulation of T cell activation in tumor immunotherapy

9:00 Discussion

9:30 Antonio Lanzavecchia The role of dendritic cells in antigen presentation and T cell activation

10:00 Discussion

10:30 Coffee Break

11:00 Giorgio Trinchieri Proinflammatory and immune mechanisms in the antitumor effect of IL-12

11:30 Discussion

12:00 Ell Gilboa *Immunotherapy of cancer with RNA transfected dendritic cells*

12:30 Discussion

13:00 Lunch

14.00 **Poster Session**

**PM, Session IV, Signaling**

Co-Chairmen: Paul Workman and P.Giuseppe Pellicci

15:00 Paolo Comoglio *Signal transduction for invasive growth*

15:30 Discussion

16:00 Coffee Break

16:30 Frank McCormick *Regulation of E2F and p53 in cancer cells and during viral infection*

17:00 Discussion

17:30 Nicholas Lydon *Structure-based discovery and development of selective protein kinase inhibitor drugs*

18:00 Discussion

18:30 Adjourn

**June 7**

**AM, Session V, Cell Regulatory Functions**

Co-Chairmen: Giulio Draetta and Alex Matter

8:00 David Livingston *P300/CDP as molecular targets*

8:30 Discussion

9:00 William Kaelin, Jr *Selective killing of cancer cells based on deregulation of E2F1*

9:30 Discussion

10:00 Coffee Break

10:30 Maria Laura Avantaggiati *Post-translational regulation of p53 by acetyltransferases: Novel targets for cancer therapy*

11:00 Discussion

11:30 Wilhelm Krek *Cell cycle control in normal and neoplastic cells: the F-box protein p45SKP2 displays its many talents*

12:00 Discussion

12:30 S.Kaye *Signal transduction inhibition, its role in cancer therapy*

13:00 Discussion

13:30 Lunch

14:30 Adjourn